Five‐year follow‐up of a randomized clinical trial comparing open surgery, foam sclerotherapy and endovenous laser ablation for great saphenous varicose veins. BJS 2018; 105: 686-691.
Published: 13th April 2018
Authors: S. Vähäaho, K. Halmesmäki, A. Albäck, E. Saarinen, M. Venermo
New treatment methods have challenged open surgery as a treatment for great saphenous vein (GSV) insufficiency, the most common being ultrasound‐guided foam sclerotherapy (UGFS) and endovenous laser ablation (EVLA). This study evaluated the long‐term results of surgery, EVLA and UGFS in the treatment of GSV reflux.
Patients with symptomatic GSV reflux were randomized to undergo either open surgery, EVLA or UGFS. The main outcome measure was the occlusion rate of the GSV at 5 years after operation.
The study included 196 patients treated during 2008–2010; of these, 166 (84·7 per cent) participated in the 5‐year follow‐up. At 5 years, the GSV occlusion rate was 96 (95 per cent c.i. 91 to 100) per cent in the open surgery group, 89 (82 to 98) per cent after EVLA and 51 (38 to 64) per cent after UGFS (
UGFS has significantly inferior occlusion rates compared with open surgery or EVLA, and results in additional treatments.Full text
You may also be interested in
Authors: H. Shiwani, P. Baxter, E. Taylor, M. A. Bailey, D. J. A. Scott
Authors: R. Mouton, C. A. Rogers, R. A. Harris, R. J. Hinchliffe
Notes: Improves 30‐day survival
Long‐term outcomes of endovenous laser ablation and conventional surgery for great saphenous varicose veins.
Authors: T. Wallace, J. El‐Sheikha, S. Nandhra, C. Leung, A. Mohamed, A. Harwood et al.
Notes: EVLA lower recurrence at 5 years
Authors: A. J. A. Meershoek, G. J. de Borst
Predicting risk of rupture and rupture‐preventing reinterventions following endovascular abdominal aortic aneurysm repair. BJS 2018; 105: 1294-1304.
Authors: I. Grootes, J. K. Barrett, P. Ulug, F. Rohlffs, S. J. Laukontaus, R. Tulamo et al.
Notes: Potential to tailor surveillance
Authors: O. Grip, A. Wanhainen, K. Michaëlsson, L. Lindhagen, M. Björck
Notes: Endo may save lives
Authors: B. M. Biccard, A. Sigamani, M. T. V. Chan, D. I. Sessler, A. Kurz, J. G. Tittley et al.
Notes: No evidence to start or stop aspirin
Authors: P. A. Coughlin, J. H. F. Rudd
Population‐based study of mortality and major amputation following lower limb revascularization. BJS 2018; 105: 1145-1154.
Authors: K. Heikkila, I. M. Loftus, D. C. Mitchell, A. S. Johal, S. Waton, D. A. Cromwell et al.
Notes: lower than previously estimated
Cost‐effectiveness of population‐based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial. BJS 2018; 105: 1283-1293.
Authors: R. Søgaard, J. S. Lindholt
Notes: Highly cost‐effective
Eight‐year follow‐up of a randomized clinical trial comparing ultrasound‐guided foam sclerotherapy with surgical stripping of the great saphenous vein. BJS 2018; 105: 692-698.
Authors: Y. L. Lam, J. A. Lawson, I. M. Toonder, N. H. Shadid, A. Sommer, M. Veenstra et al.
Notes: Surgery better